A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTRX-07 in Subjects With Mild Cognitive Impairment or Mild to Moderate Alzheimer's Disease
Latest Information Update: 20 Nov 2026
At a glance
- Drugs NTRX 07 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Acronyms SPPN-AD
- Sponsors NeuroTherapia
Most Recent Events
- 13 Jul 2026 According to a NeuroTherapia media release, data from this will be presented at the Alzheimer's Association International Conference (AAIC) 2026 during the Monday July 13th poster session.
- 07 Apr 2026 Status changed from recruiting to completed.
- 10 Jul 2025 Status changed from planning to recruiting.